Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096

• Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations
  

Espoo, Finland, 19 February 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage biotech company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces that it is leading a consortium that has been selected for, pending final negotiation, an EUR 8.0 million grant from the Horizon Europe 2025 Research and Innovation program, under the ‘Boosting the translation of biotech research into innovative health therapies’ topic.

The consortium, which also includes multiple European university hospitals, will use the funding to support the execution of Herantis’ planned Phase 2, double-blind, placebo-controlled, randomized efficacy and safety study of subcutaneously administered HER-096 in patients with early-stage Parkinson’s disease. Herantis intends to initiate the study as soon as the necessary preparations, including regulatory approvals and securing additional resources, are completed.

Antti Vuolanto, CEO of Herantis Pharma, said: “We are absolutely delighted to have been selected for this non-dilutive funding from Horizon Europe. This grant will make a meaningful contribution to the funding of our Phase 2 proof-of-concept study for HER-096, the resourcing of which we are continuing to discuss with potential investors and strategic partners. Being selected from a highly competitive field of innovative European companies further validates our scientific approach and underscores the potential of HER-096 to improve outcomes for people living with Parkinson’s disease. I would like to thank the European Commission for its support and look forward to providing further updates once the agreement is signed, and the study design has been finalized.”

The ‘Boosting the translation of biotech research into innovative health therapies’ topic, which forms part of the wider Horizon Europe 2025 Health initiative, is designed to accelerate the translation of promising biotech research into clinical development and aims to deliver the following outcomes:

• Faster access to innovative therapies for healthcare providers, researchers and patients
• Increased number of clinical trials evaluating novel biotech therapeutic approaches conducted within the European Union
• Strengthened competitiveness of small and medium-size enterprises (SMEs) in the EU and Associated Countries within the health biotech sector

Schreibe Deinen Kommentar